# Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

> **NCT05926427** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 25 (estimated)

## Conditions studied

- CNS Lymphoma

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Rituximab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05926427
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-10
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926427, "Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05926427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*